Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00614042
Recruitment Status : Completed
First Posted : February 13, 2008
Last Update Posted : June 28, 2017
Sponsor:
Information provided by (Responsible Party):
Aptevo Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and non-Hodgkin's lymphoma.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia (CLL) Non-Hodgkin's Lymphoma (NHL) Drug: TRU-016 (anti-CD37 protein therapeutic) Phase 1

Detailed Description:
This Phase 1/1b open-label study consists of two parts. The initial portion is a Phase 1 dose-escalation study evaluating the safety and tolerability of TRU-016 administered over a 4-week period to patients with relapsed chronic lymphocytic leukemia (CLL). It will identify the MTD and evaluate the pharmacokinetics and immunogenicity of TRU-016. Upon demonstrating satisfactory safety and tolerability in the Phase 1 portion, a Phase 1b expansion cohort will be enrolled to further characterize the safety of the selected dose from the first stage of the study and safety and to estimate the clinical activity of TRU-016 in patients with treatment-naive CLL, relapsed CLL and non-Hodgkin's lymphoma.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma
Study Start Date : January 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1
Dose escalation and expansion cohorts
 Drug: TRU-016 (anti-CD37 protein therapeutic)
TRU-016 administered via IV infusion weekly for 8 weeks and then monthly


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and tolerability of TRU-016 administered IV in patients with CLL or NHL [ Time Frame: 4 weeks after treatment ]

Secondary Outcome Measures :
  1. Preliminary indication of response as defined by NCI 1996 criteria [ Time Frame: 3 months after treatment ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of chronic lymphocytic lymphoma or small lymphocytic lymphoma (Phase 1) or relapsed/refractory NHL (Phase 1b)
  • Previous treatment with at least one fludarabine-containing regimen

  • Demonstrate at least one of the following criteria for active disease requiring treatment:

    • a)progressive splenomegaly and/or lymphadenopathy;
    • b)anemia or thrombocytopenia due to bone marrow involvement;
    • c)unintentional weight loss >10% over preceding 6-month period;
    • d) NCI Grade 2 or 3 fatigue;
    • e) fevers >100.5 F or night sweats for > 2 weeks without infection;
    • f) progressive lymphocytosis with increase of >50% over a 2-month period or anticipated doubling time of < 6 months.
  • ECOG performance status </= 2
  • SGOT, SGPT </= 2.0 x upper limit of normal
  • ANC >/= 500/uL
  • Platelets >/= 30,000/uL
  • Discontinued previous anticancer or investigational therapy for at least 30 days

Exclusion Criteria:

  • Treatment with rituximab within 30 days or alemtuzumab(Campath)or radioimmune therapy within 12 weeks
  • ANC </= 500/uL
  • Platelets </= 30,000/mm3
  • Previous or concurrent additional malignancy
  • Significant concurrent medical diseases or conditions
  • Hepatitis B surface antigen or hepatitis B core antibody positive
  • Pregnant or breastfeeding
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00614042


Locations
Layout table for location information
United States, Alabama
For additional information regarding sites for this trial call 919-319-9374
Birmingham, Alabama, United States, 35294
United States, Georgia
For additional information regarding sites for this trial call 919-319-9374
Augusta, Georgia, United States, 30912
United States, Massachusetts
For additional information regarding sites for this trial call 919-319-9374
Boston, Massachusetts, United States, 02111
United States, Nevada
For additional information regarding sites for this trial call 919-319-9374
Las Vegas, Nevada, United States, 89135
United States, North Carolina
For additional information regarding sites for this trial call 919-319-9374
Durham, North Carolina, United States, 27710
United States, Oregon
For additional information regarding sites for this trial call 919-319-9374
Portland, Oregon, United States, 97239
United States, Washington
For additional information regarding sites for this trial call 919-319-9374
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Aptevo Therapeutics
Investigators
Layout table for investigator information
Study Director: Scott Stromatt, MD Aptevo Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Aptevo Therapeutics
ClinicalTrials.gov Identifier: NCT00614042    
Other Study ID Numbers: 16007
First Posted: February 13, 2008    Key Record Dates
Last Update Posted: June 28, 2017
Last Verified: June 2017
Keywords provided by Aptevo Therapeutics:
CLL
NHL
TRU-016
chronic lymphocytic leukemia
non-Hodgkin's lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
 Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell